CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
“Company”) held its annual shareholders meeting for the fiscal
year ended December 31, 2015 (the “Annual Meeting”). Holders of
27,271,585 shares of the Company’s common stock were present in
person or by proxy at the Annual Meeting, representing 62.6% of
the total outstanding shares of common stock and therefore
constituting a quorum of more than one-third of the shares
outstanding and entitled to vote at the Annual Meeting as of the
record date.
shareholders at the meeting are as follows. No broker non-votes
were counted for any of the proposals as the Company chose to.
|
1.
|
A proposal to elect three independent director nominees to
our Board of Directors to serve until the next annual meeting and until their successors are elected and qualified: |
|||||||
|
Director’s Name
|
Votes For
|
Votes Withheld
|
||||||
|
Gene Michael Bennett
|
24,790,576
|
2,481,009
|
||||||
|
Yingwen Zhang
|
24,789,576
|
2,482,009
|
||||||
|
Baowen Dong
|
24,789,576
|
2,482,009
|
|
2.
|
A proposal to approve, on a non-binding, advisory basis,
the compensation of our named executive officer as disclosed in the proxy statement to the compensation disclosure rules of the Securities and Exchange Commission. |
|
For
|
Against
|
Abstain
|
|||
|
24,895,511
|
2,347,574
|
58,500
|
|
3.
|
A proposal to approve, on a non-binding, advisory basis,
the frequency of the advisory vote on executive compensation: |
|
One Year
|
Two Years
|
Three Years
|
Abstain
|
|||
|
7,698,383
|
11,445
|
19,558,977
|
2,780
|
Baowen Dong were elected to serve as independent directors; the
compensation of registrant’s named executive officers was
approved; and the frequency of the advisory vote on executive
compensation was decided to be once every three years.
About CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI)
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People’s Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others. CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI) Recent Trading Information
CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI) closed its last trading session down -0.010 at 0.230 with 502,513 shares trading hands.
